Insight into the immunopathogenesis of crystal-induced inflammation has opened the door to a new approach to therapy. Could interleukin-1 antagonists be the answer to managing acute gout?

For gout, xanthine oxidase (XO) inhibitors are the choice for first-line urate-lowering therapy (ULT) according to the 2020 American College of Rheumatology Guideline for the Management of Gout ...

Treatment fails in some ... They conducted an open-label, single-injection, dose-escalation, phase I trial with 13 patients with symptomatic refractory gout and a plasma uric acid concentration ...

for about 3 to 6 months after the beginning of that therapy it actually may be more common to have more gout attacks... which are actually physical uric acid precipitants that develop around ...

Studies have suggested that IL-1 beta activation leads to IL-6 production, which could provide an alternative to current therapeutic strategies.